Longevity & AgingResearch PaperOpen Access

Inflammaging is a druggable network of signaling hubs, not just a CRP number

A narrative review argues age-related inflammation runs through NF-κB, NLRP3 and cGAS–STING hubs that drugs can modify. Evidence is mostly from mice.

Thursday, November 19, 2026 1 view
Published in Curr Issues Mol Biol
researcher pipetting samples into a multiwell plate beside a microscope in a bright immunology lab

Summary

This narrative review argues that the chronic low-grade inflammation of aging, called inflammaging, is better understood as a network of targetable biological circuits than as a blood test result. Markers like IL-6, TNF-α and CRP can mislead: IL-6, for example, is released by working muscle and has anti-inflammatory, insulin-sensitizing effects. The authors describe several upstream sources: immune aging, gut dysbiosis, metabolic dysfunction and senescent cells. These converge on a few central hubs: NF-κB, the NLRP3 inflammasome, cGAS–STING, JAK/STAT and p38 MAPK. In mice, the review cites the following results: - Transplanting aged microbiota into young germ-free mice induced gut inflammation. - Clearing senescent cells reduced liver fat and inflammation. - The NLRP3 inhibitor MCC950 eased metabolic dysfunction in aged mice, alongside increased autophagy and mTOR inhibition. No lifespan results appear in the supplied text, and human evidence in it is limited to association data.

Detailed Summary

Inflammaging, the persistent low-grade inflammation of older age, is linked to cardiometabolic disease, neurodegeneration, frailty and poor tissue regeneration. This review argues that circulating markers such as IL-6, TNF-α, IL-1β and CRP cannot capture inflammaging's causes or tissue specificity, and can mislead. IL-6 is released by contracting muscle, where it induces IL-10 and inhibits TNF-α production. Leptin and TNF-α also have essential physiological roles. The authors propose treating inflammaging as a network of discrete, targetable nodes, which they call 'druggable inflammaging'.

The review is narrative, not systematic. Searches of PubMed and Scopus (last updated January 2026) found about 420 records. About 160 were assessed in full text, and 100 were included. Preclinical, translational and clinical work were all considered. The studies described in the supplied text are predominantly in mice.

The review describes upstream sources first. In naturally aged mice, single-cell multiorgan profiling showed fewer CD4+ and CD8+ T cells, NK cells and plasmacytoid dendritic cells. It also showed expanded myeloid lineages and higher MHC class II on macrophages. Aged mice showed gut barrier disruption, higher circulating LPS-binding protein and enhanced TLR4 signaling. Transplanting aged-donor microbiota into young germ-free mice was sufficient to induce colonic inflammatory gene expression and systemic markers of innate immune activation, a causal result in mice. Human cohort data in nonagenarians and centenarians show age-associated remodeling of the gut microbiome and metabolome alongside inflammation-related changes; this is association-level evidence. In C57BL/6 mice, ad libitum feeding with aging caused ectopic liver fat, while dietary restriction did not. Clearing senescent cells, either genetically in INK-ATTAC mice or with dasatinib plus quercetin, reduced hepatic steatosis and inflammatory immune infiltration. Multitissue mapping in mice suggests senescence is heterogeneous and can create an 'aged-like inflamed niche' that restricts stem-cell function.

These drivers converge on a small set of hubs: NF-κB, NLRP3, cGAS–STING, JAK/STAT and p38 MAPK. Tonic IKK–NF-κB activity sustains low-level inflammatory mediator and SASP expression; the review cites in vivo work in growth hormone receptor and PAPP-A knockout mice. In naturally aged mice, cGAS–STING activation in brain-resident immune cells drives a type I interferon response associated with neuronal loss and cognitive impairment. This suggests nucleic acid sensing actively drives inflammaging rather than just reflecting it. Cardiovascular mouse studies serve as proof of concept for targeting these hubs: - Dasatinib plus quercetin aided myocardial repair after infarction in female C57BL/6J mice. - Targeting the p16INK4a–STAT3–NLRP3 axis, with senomorphic nanotherapeutics or cardiomyocyte-specific p16INK4a knockout, attenuated STAT3/NLRP3-driven inflammaging and tissue dysfunction. - The NLRP3 inhibitor MCC950 attenuated metabolic dysfunction in aged mice, alongside increased autophagy and mTOR pathway inhibition.

These are mechanism and function results in mice. The supplied text reports no lifespan outcome and no human intervention trial for these targets. They still need testing in humans, on clinical outcomes, before routine use. The supplied text was truncated partway through Section 4, so later material on JAK/STAT, p38 MAPK, additional therapies and the authors' conclusions is not covered here.

Key Findings

  • Aged-donor microbiota transplanted into young germ-free mice was sufficient to induce colonic inflammatory gene expression and systemic markers of innate immune activation (causal mouse result).
  • Clearing senescent cells genetically (INK-ATTAC) or with dasatinib plus quercetin reduced hepatic steatosis and inflammatory immune infiltration in aged ad libitum-fed C57BL/6 mice.
  • In naturally aged mice, cGAS–STING activation in brain-resident immune cells drove a type I interferon response associated with neuronal loss and cognitive impairment (mouse mechanism).
  • The NLRP3 inhibitor MCC950 attenuated metabolic dysfunction in aged mice, alongside increased autophagy and mTOR inhibition. This is a mouse mechanism and function result; no lifespan outcome is reported in the supplied text.
  • Targeting the p16INK4a–STAT3–NLRP3 axis, and dasatinib plus quercetin after myocardial infarction, attenuated inflammaging and supported cardiac tissue repair in mice.
  • Human evidence in the supplied text is association-level: microbiome and metabolome remodeling with inflammation-related changes in nonagenarians and centenarians.

Methodology

This is a narrative review using PubMed and Scopus, last searched January 2026. About 420 records were identified, about 160 were assessed in full text and 100 were included. The review was English-only and excluded conference abstracts, editorials and gray literature. It considered preclinical, translational and clinical studies, but no formal risk-of-bias assessment or quantitative pooling was described. The studies described in the supplied text are predominantly mouse experiments, plus one human association cohort.

Study Limitations

The review is narrative, and study selection may favor the 'druggable inflammaging' thesis. The evidence in the supplied text is mostly from mice. The only human data described is an association cohort. No lifespan outcomes are reported in the supplied text. No conflicts of interest statement was present in the supplied text, which was truncated partway through Section 4.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: